跳至主要内容
临床试验/NCT05150834
NCT05150834Unknown不适用

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine

Korea University Guro Hospital1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2021年2月25日最近更新:
适应症

试验速览

阶段
不适用
入组人数
53
试验地点
1
主要终点
Taxonomic biomarkers predicting immune responses

研究概览

简要总结

Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • People assigned to get either BNT162b2 or ChAdOx1 vaccines
  • informed concents

排除标准

  • Participants were excluded if they had a history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs.

结局指标

主要结局

Taxonomic biomarkers predicting immune responses

时间窗: before the administration of first-dose

This study aimed to analyze whether fecal microbiota composition before vaccination was associated with immmune response level

次要结局

  • Antibody titres after the first dose vaccination(3weeks from the first-dose administration in BNT162b2 group, 8-12weeks from the first-dose administration in ChAdOx1)
  • Antibody titres after the second dose vaccination(3 weeks from the second dose administration in both BNT162b2 and ChAdOx1 groups)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hye Seong

clinical professor

Korea University Guro Hospital

研究点 (1)

Loading locations...

相似试验

Gut Microbiota, the Potential Key to Modulating... | 临床试验